Tuesday, July 28, 2015

Rodman starts Second Sight at buy

Rodman starts Second Sight at buy

July 6, 2015 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Second Sight Medical Products (NASDAQ:EYES) with a “buy” rating and a 12-month price target of $21. The stock closed at $14.05 on Friday. Second Sight is a pioneer in commercializing implantable prosthetic devices that restore functional vision to blind patients. “We view Second Sight as an attractive […]

ROTH adds Michael Higgins to biotech research team

ROTH adds Michael Higgins to biotech research team

May 6, 2015 by · Leave a Comment 

Tweet Michael Higgins has joined ROTH Capital Partners as a senior research analyst covering the biotechnology and specialty pharmaceuticals sectors. Prior to joining ROTH, Mr. Higgins covered the biopharmaceuticals sector for Rodman & Renshaw, where his coverage included generic drug companies as well as clinical-stage biotechnology companies. In a statement, Mr. Higgins said his goal […]

Elemer Piros joins Roth biotech team

Elemer Piros joins Roth biotech team

February 19, 2015 by · Leave a Comment 

Tweet Elemer Piros has joined Roth Capital Partners as a senior research analyst covering the biotechnology sector. Prior to joining Roth, Dr. Piros was interim CEO of eMMUNITY, an immunotherapy startup company. He was previously a senior biotechnology analyst at Rodman & Renshaw and Burrill Securities. Dr. Piros was ranked as the No. 1 biotechnology […]

HCW expands biotech practice with four hires

HCW expands biotech practice with four hires

June 20, 2014 by · Leave a Comment 

Tweet H.C. Wainwright & Co has hired one managing director in equity research and three VPs in investment banking to further enhance its biotechnology practice. Swayampakula Ramakanth (“RK”) has joined HCW in equity research as managing director, senior biotechnology analyst.  Prior to joining HCW, Dr. Ramakanth was an analyst at Jefferies and Merrill Lynch, covering […]

Wainwright bulks up biotech coverage

Wainwright bulks up biotech coverage

September 6, 2013 by · Leave a Comment 

Tweet H.C. Wainwright & Co. has made two significant additions to its Life Sciences Equity Research group – Reni Benjamin and Caroline Stewart – to further strengthen its position in the biotechnology and life sciences sectors. In June, Andrew Fein joined HCW to comprise the firm’s senior biotechnology research team. Dr. Benjamin joins HCW as […]

H.C. Wainwright hires veteran biotech analyst Andrew Fein

H.C. Wainwright hires veteran biotech analyst Andrew Fein

May 30, 2013 by · Leave a Comment 

Tweet Andrew Fein has joined H.C. Wainwright & Co. as managing director, senior biotechnology analyst, to cover companies in the biotechnology and life sciences sectors. Mr. Fein, who will be based in HCW’s New York office, has 13 years of experience in healthcare and biotechnology equity research. He was previously a senior analyst at Chardan […]

DirectMarkets in pact to sell broker-dealer unit

DirectMarkets in pact to sell broker-dealer unit

July 2, 2012 by · Leave a Comment 

Tweet Direct Markets Holdings (NASDAQ:MKTS) has entered into a nonbinding letter of intent for the sale of Rodman & Renshaw LLC, its broker-dealer subsidiary, to an entity controlled by Michael Vasinkevich, one of the company’s founders and former vice chairman of the board. Terms include the assumption of specified liabilities, including certain leasehold obligations, accounts […]

Rodman ups PharmAthene to market outperform

Rodman ups PharmAthene to market outperform

June 4, 2012 by · Leave a Comment 

Tweet Rodman & Renshaw has upgraded PharmAthene (AMEX:PIP) to “market outperform,” with a new 12-month price target of $7, from “market perform,” after a Delaware court judge issued a final judgment with “favorable economics” to PharmAthene in its dispute with SIGA Technologies. Shares of PharmAthene closed at $1.56 on Friday. Last September, the court ruled […]

Novadaq underwriters exercise over-allotment

Novadaq underwriters exercise over-allotment

April 9, 2012 by · Leave a Comment 

Tweet Prior to the closing of a public offering of 6.1 million common shares at $5.75 a piece, underwriters for Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) exercised in full an option to purchase an additional 915,000 common shares at the same price solely to cover overallotments. After deducting commissions and other expenses, Novadaq received net proceeds of […]

Rodman starts Affymax at market outperform

Rodman starts Affymax at market outperform

March 23, 2012 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of Affymax (NASDAQ:AFFY) with a “market outperform” rating and $20 price target, pointing out that the company could soon chip away at Amgen’s 20-year monopoly in the dialysis space. The stock closed at $12.44 on Thursday. Analyst Michael King writes that Affymax is on the brink of FDA […]

Next Page »

Email Newsletters with Constant Contact
Google+